You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Provention Bio Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Provention Bio Company Info
Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses. Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.
News & Analysis
Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker.
On a volatile market day, companies are still looking for smart combinations.
The company got approval for its lead type 1 diabetes therapy.
You may not want to be too quick to pull the trigger.
It could be a make-or-break end of the year for the company.
Are the Street's predictions too optimistic?
The momentum from the company's good news last week is continuing this week.
The company plans to refile for approval of its experimental type 1 diabetes therapy.
PRVB earnings call for the period ending September 30, 2021.
PRVB earnings call for the period ending June 30, 2021.
PRVB earnings call for the period ending March 31, 2021.
PRVB earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.